Equilibrative Nucleoside Transporter 1

A subtype of equilibrative nucleoside transporter proteins that is sensitive to inhibition by 4-nitrobenzylthioinosine.

Also Known As:

Equilibrative NBMPR-Sensitive Nucleoside Transporter; Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter; SLC29A1 Transporter; Solute Carrier Family 29 (Nucleoside Transporters), Member 1; Equilibrative NBMPR Sensitive Nucleoside Transporter; Equilibrative Nitrobenzylmercaptopurine Riboside Sensitive Nucleoside Transporter

Networked: 127 relevant articles (3 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Carrier Proteins: 12999
    - Membrane Transport Proteins: 589
      - Solute Carrier Proteins: 34
        Equilibrative Nucleoside Transport Proteins
        Equilibrative Nucleoside Transporter 1: 127
        C elegans equilibrative nucleoside transporter 1
        human SLC29A1 protein
        mouse SLC29A1 protein
        rat Slc29a1 protein
      - Nucleobase, Nucleoside, Nucleotide, and Nucleic Acid Transport Proteins
        Nucleoside Transport Proteins: 164
        Equilibrative Nucleoside Transport Proteins
        Equilibrative Nucleoside Transporter 1: 127
        C elegans equilibrative nucleoside transporter 1
        human SLC29A1 protein
        mouse SLC29A1 protein
        rat Slc29a1 protein
  - Membrane Proteins: 10078
    - Membrane Transport Proteins: 589
      - Solute Carrier Proteins: 34
        Equilibrative Nucleoside Transport Proteins
        Equilibrative Nucleoside Transporter 1: 127
        C elegans equilibrative nucleoside transporter 1
        human SLC29A1 protein
        mouse SLC29A1 protein
        rat Slc29a1 protein
      - Nucleobase, Nucleoside, Nucleotide, and Nucleic Acid Transport Proteins
        Nucleoside Transport Proteins: 164
        Equilibrative Nucleoside Transport Proteins
        Equilibrative Nucleoside Transporter 1: 127
        C elegans equilibrative nucleoside transporter 1
        human SLC29A1 protein
        mouse SLC29A1 protein
        rat Slc29a1 protein

Experts

1.	Mackey, John R: 12 articles (12/2019 - 01/2002)
2.	Cass, Carol E: 11 articles (01/2014 - 01/2002)
3.	Lai, Raymond: 7 articles (11/2016 - 10/2004)
4.	Young, James D: 7 articles (09/2010 - 01/2002)
5.	Pastor-Anglada, Marçal: 5 articles (08/2016 - 07/2005)
6.	Dabbagh, Laith: 5 articles (04/2005 - 01/2002)
7.	Xia, Yang: 4 articles (01/2020 - 01/2012)
8.	Coe, Imogen R: 4 articles (01/2017 - 01/2012)
9.	Sobrevia, Luis: 4 articles (01/2015 - 10/2004)
10.	Hwang, Jin-Hyeok: 3 articles (06/2021 - 08/2017)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 05/01/2023 - "A viral gene vector containing the pancreatic cancer-targeting promoter MUC1 for specific transcription of equilibrative nucleoside transporter 1 (ENT1) and NIS (nuclide transport channel) was employed. " 11/01/2013 - "The aim of this mini-review is to summarize the current information concerning the prognostic and predictive role of SLC29A1 transporter (hENT1) expression in pancreatic cancer. " 08/01/2015 - "Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial." 07/14/2014 - "High human equilibrative nucleoside transporter 1 (hENT1)-expression has shown a survival benefit in pancreatic cancer patients treated with gemcitabine in several studies. " 07/01/2014 - "Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody."
2.	Neoplasms (Cancer) 09/01/2010 - "The current study was undertaken to determine whether equilibrative nucleoside transporter 1 (ENT1) is important for (18)F-FLT uptake in normal tissues and tumors. " 01/01/2016 - "In this study, patients receiving more than four cycles of adjuvant gemcitabine and harboring Human equilibrative nucleoside transporter 1 (hENT-1, the major transporter involved in gemcitabine intracellular uptake) on tumor cell membrane had a longer disease-free survival compared with patients negative or positive for hENT-1 only in the cytoplasm of tumor cells. " 12/01/2019 - "Gemcitabine, the primary drug for the treatment of pancreatobiliary cancer (PBC), requires human equilibrative nucleoside transporter 1 (hENT1) to enter cells. " 12/01/2019 - "Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-Analysis." 01/01/2018 - "Human equilibrative nucleoside transporter 1 (hENT1) transports nucleoside analogue drugs across cellular membranes and is necessary for the uptake of many anti-tumor drugs. "
3.	Thrombosis (Thrombus) 04/01/2016 - "In addition to P2Y12 receptor blockade, ticagrelor is unique in having the only well-documented additional target of inhibition, the equilibrative nucleoside transporter 1. The current review will address the effects of P2Y12 receptor antagonists beyond platelets and the protection against arterial thrombosis. "
4.	Cholangiocarcinoma 01/01/2023 - "Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study." 01/01/2019 - "Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments." 05/01/2012 - "Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma." 08/01/2012 - "The aim of this study was to evaluate whether intratumoral human equilibrative nucleoside transporter 1 (hENT1) expression can predict the survival of advanced cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy (AGC) after surgical resection. " 08/01/2012 - "Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection."
5.	Adenocarcinoma 12/02/2010 - "Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions." 06/01/2021 - "The study aimed to evaluate the clinical outcomes of tailored adjuvant chemotherapy according to human equilibrative nucleoside transporter 1 (hENT1) expression in resected pancreatic ductal adenocarcinoma (PDA). " 04/01/2016 - "Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients." 10/23/2019 - "Evidence on equilibrative nucleoside transporter 1 (ENT1) and microRNA-21 (miR‑21) is not yet sufficiently convincing to consider them as prognostic biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC). " 07/01/2017 - "Expression of human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma (PDAC) has been postulated to be a marker of sensitivity to gemcitabine. "

Related Drugs and Biologics

1.	Gemcitabine
2.	Ribonucleotide Reductases (Ribonucleotide Reductase)
3.	Ticagrelor
4.	Purinergic P2Y Receptor Antagonists
5.	Platinum
6.	Thymidylate Synthase
7.	Deoxycytidine Kinase
8.	Dihydrouracil Dehydrogenase (NADP) (Dihydropyrimidine Dehydrogenase)
9.	Cytarabine (Cytosar-U)
10.	Messenger RNA (mRNA)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Adjuvant Chemotherapy
4.	Chemoradiotherapy
5.	Blood Component Removal (Apheresis)